Lupus (SLE) Clinical Research Study

About This Study

This clinical study is evaluating an investigational treatment for adults with systemic lupus erythematosus (SLE). The study medication aims to reduce disease flares, improve symptoms, and allow reduction of steroid doses while maintaining disease control.

What is Lupus (SLE)?

Systemic lupus erythematosus is a chronic autoimmune disease in which the immune system attacks healthy tissue throughout the body. It can affect the joints, skin, kidneys, brain, heart, and lungs. Lupus is characterized by periods of flares (worsening symptoms) and remission. Common symptoms include joint pain, fatigue, skin rashes (including the characteristic butterfly rash), and sensitivity to sunlight.

Learn more about lupus at Overlake Arthritis →

Who May Qualify

• Adults 18 years or older
• Diagnosed with systemic lupus erythematosus (SLE)
• Positive ANA or anti-dsDNA antibodies
• Active disease or history of flares despite current treatment
• Currently taking lupus medication (hydroxychloroquine, immunosuppressants, or steroids)

What Participation Involves

• Screening: Comprehensive evaluation including blood work, urine tests, and disease activity assessment
• Treatment: Approximately 52 weeks of study medication
• Visits: Regular monitoring every 4 weeks
• Assessments: Disease activity scores, laboratory tests, quality of life questionnaires

Compensation

• All study-related medical care and lab work at no cost
• Investigational medication provided free of charge
• Compensation for time and travel expenses